capricor therapeutics, inc. (nasdaq: capr) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways. capricor’s lead candidate, cap-1002, is an “off-the-shelf” cardiac cell therapy that is currently in clinical development for the treatment of duchenne muscular dystrophy (dmd). cap-1002 consists of allogeneic cardiosphere-derived cells, or cdcs, a unique population of cells which include progenitor cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. cdcs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 140 human subjects across several clinical trials. capricor has
Company profile
Ticker
CAPR
Exchange
Website
CEO
Linda Marban
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Nile Therapeutics, Inc., SMI PRODUCTS INC
SEC CIK
Corporate docs
Subsidiaries
Capricor, Inc. ...
CAPR stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
1 Apr 24
DEF 14A
Definitive proxy
29 Mar 24
PRE 14A
Preliminary proxy
20 Mar 24
10-K
2023 FY
Annual report
11 Mar 24
8-K
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
29 Feb 24
S-8
Registration of securities for employees
16 Feb 24
8-K
Other Events
11 Jan 24
8-K
Other Events
11 Dec 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
14 Nov 23
Transcripts
CAPR
Earnings call transcript
2023 Q4
29 Feb 24
CAPR
Earnings call transcript
2023 Q3
14 Nov 23
CAPR
Earnings call transcript
2023 Q2
7 Aug 23
CAPR
Earnings call transcript
2023 Q1
11 May 23
CAPR
Earnings call transcript
2022 Q4
15 Mar 23
CAPR
Earnings call transcript
2022 Q3
11 Nov 22
CAPR
Earnings call transcript
2022 Q2
11 Aug 22
CAPR
Earnings call transcript
2022 Q1
11 May 22
CAPR
Earnings call transcript
2021 Q4
10 Mar 22
CAPR
Earnings call transcript
2021 Q3
10 Nov 21
Latest ownership filings
4
EARL M COLLIER JR
25 Apr 24
4
David B Musket
24 Apr 24
SC 13G
HIGHBRIDGE CAPITAL MANAGEMENT LLC
7 Feb 24
4
Mike Kelliher
4 Jan 24
4
Philip J Gotwals
4 Jan 24
4
Paul Gisbert Auwaerter
4 Jan 24
4
David B Musket
4 Jan 24
4
GEORGE W DUNBAR JR
4 Jan 24
4
Karimah Es Sabar
4 Jan 24
4
EARL M COLLIER JR
4 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 8.98 mm | 8.98 mm | 8.98 mm | 8.98 mm | 8.98 mm | 8.98 mm |
Cash burn (monthly) | 284.16 k | (no burn) | 2.29 mm | 2.57 mm | 2.93 mm | 1.74 mm |
Cash used (since last report) | 1.96 mm | n/a | 15.79 mm | 17.75 mm | 20.23 mm | 12.02 mm |
Cash remaining | 7.02 mm | n/a | -6.80 mm | -8.76 mm | -11.24 mm | -3.04 mm |
Runway (months of cash) | 24.7 | n/a | -3.0 | -3.4 | -3.8 | -1.7 |
Institutional ownership, Q2 2023
8.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 31 |
Opened positions | 6 |
Closed positions | 4 |
Increased positions | 11 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 12.03 bn |
Total shares | 2.62 mm |
Total puts | 16.70 k |
Total calls | 48.70 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 1.15 mm | $5.48 bn |
BLK Blackrock | 410.92 k | $1.96 bn |
Geode Capital Management | 298.32 k | $1.43 bn |
NTRS Northern Trust | 105.51 k | $504.32 mm |
STT State Street | 84.92 k | $405.94 mm |
BK Bank Of New York Mellon | 84.54 k | $404.12 mm |
LPL Financial | 78.44 k | $374.92 mm |
MS Morgan Stanley | 53.13 k | $253.97 mm |
Susquehanna International | 48.64 k | $232.48 mm |
Renaissance Technologies | 46.42 k | $222.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Apr 24 | Musket David B | Common Stock | Option exercise | Acquire M | No | No | 1.39 | 16,156 | 22.46 k | 47,692 |
23 Apr 24 | Musket David B | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.39 | 5,750 | 7.99 k | 0 |
23 Apr 24 | Musket David B | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.39 | 3,000 | 4.17 k | 0 |
23 Apr 24 | Musket David B | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.39 | 2,750 | 3.82 k | 0 |
23 Apr 24 | Musket David B | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.39 | 1,050 | 1.46 k | 0 |
23 Apr 24 | Musket David B | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.39 | 2,750 | 3.82 k | 0 |
23 Apr 24 | Musket David B | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.39 | 856 | 1.19 k | 0 |
23 Apr 24 | Collier Earl M JR | Common Stock | Option exercise | Acquire M | No | No | 1.39 | 30,000 | 41.70 k | 56,856 |
23 Apr 24 | Collier Earl M JR | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.39 | 30,000 | 41.70 k | 53,000 |
2 Jan 24 | Paul Gisbert Auwaerter | Stock Option Common Stock | Grant | Acquire A | No | No | 5.12 | 6,760 | 34.61 k | 6,760 |
News
HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target
25 Apr 24
HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target
1 Mar 24
Recap: Capricor Therapeutics Q4 Earnings
29 Feb 24
Capricor Therapeutics Q4 2023 GAAP EPS $(0.020) Beats $(0.200) Estimate, Sales $12.088M Beat $10.600M Estimate
29 Feb 24
Earnings Scheduled For February 29, 2024
29 Feb 24